Month: September 2022

Dr. Dreismann, Former Roche Molecular Diagnostics CEO, and Mr. Tibbitts, a Highly-accomplished Life-Sciences Executive, Provide Extensive Experience in Diagnostics and Financial Strategy Company to Hold Extraordinary General Meeting Week of December 12, 2022 BERKELEY, Calif. and MAINZ, Germany, Sept. 28, 2022 (GLOBE NEWSWIRE) — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that its Nominating Committee and Board of Directors nominated Dr. Heiner Dreismann as Chairman of the Board and Gregory Tibbitts to its Board of Directors. The Company’s Board of Directors intends to call an extraordinary general meeting the week of December 12, 2022, to vote on the nominations. “As we continue to build strength throughout...

EVLI PLC STOCK EXCHANGE RELEASE SEPTEMBER 28, 2022 AT 2.00 PM (EET/EEST) NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Evli Plc (“Evli”) and EAB Group Plc (“EAB”) announced on May 31, 2022 that Evli and EAB had signed a combination agreement (the “Combination Agreement”) and a merger plan (the “Merger Plan”) on the combination of the companies through a merger (the “Combined Company”). The combination of Evli and EAB is executed through a statutory absorption merger in accordance with the Finnish Companies Act whereby all assets and liabilities of EAB are transferred without a liquidation procedure to Evli (the “Merger”). The conditions of the completion of the merger The conditions of the completion according to the Combination Agreement...

STAMFORD, Conn., Sept. 28, 2022 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that its licensing partner Maruishi Pharmaceutical Co., Ltd. submitted a New Drug Application (NDA) in Japan for approval of difelikefalin for the treatment of pruritus in hemodialysis patients. “The NDA submission represents important progress toward bringing difelikefalin injection to hemodialysis patients suffering from pruritus in Japan,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. “In collaboration with our partners, we look forward to making difelikefalin injection available to healthcare providers and hemodialysis patients around the world who...

Clinical program advancement represents key milestone for Cornerstone underscoring its commitment to the development of lead compound, devimistat, in pancreatic cancer Cranbury, Sept. 28, 2022 (GLOBE NEWSWIRE) — September 28, 2022 – Cornerstone Pharmaceuticals, Inc., a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the initiation of a Phase 1 clinical trial evaluating CPI-613® (devimistat) in combination with chemoradiation for the treatment of advanced pancreatic cancer. Devimistat is the company’s first-in-class lead compound designed to target enzymes that are involved in cancer cell energy metabolism found within the mitochondria of cancer cells. “The initiation of this Phase 1 trial is an important milestone for Cornerstone and demonstrates our continued commitment...

Microbix to Repurchase up to 5% of its outstanding shares over 12 months MISSISSAUGA, Ontario, Sept. 28, 2022 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces the initiation of a Normal Course Issuer Bid (“NCIB”) program for the repurchase and cancellation of outstanding common shares. Specifically, the NCIB enables Microbix to repurchase up to 6,949,568 Common Shares (“Shares“), that being approximately five percent (5%) of the 138,991,374 Shares outstanding as at September 26, 2022, through the facilities of the Toronto Stock Exchange (“TSX”) over a 12 month period starting on October 3, 2022 and ending on October 2, 2023. The actual number of Shares repurchased pursuant to the NCIB will be determined by management. The...

On September 28th, 2022, Kvalitena AB (publ), Reg. No. 556527-3314, a company incorporated and registered in Sweden (“Kvalitena”), entered into a Share Purchase Agreement with vehicles managed by the Starboard group (“Starboard”) in which Kvalitena sold approximately 10% (ten percent) of the shares issued by Maha Energy AB (publ), Reg. No. 559018-9543, a public limited liability company incorporated under the laws of Sweden (“Company”), to Starboard.  Starboard is a Brazilian investment management firm with offices in São Paulo, Rio de Janeiro, and Madrid. Its extensive experience and credibility with market participants in the Brazilian space allow Starboard to find unique investment opportunities and provide solutions to highly complex situations. Starboard’s expertise has enabled the development...